Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 108Stomach Neoplasms 68Pancreatic Neoplasms 33Neoplasms 24Lymphoma, Large B-Cell, Diffuse 22Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 18Rectal Neoplasms 17Colonic Neoplasms 17Esophageal Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 13Adenocarcinoma 13Carcinoma, Hepatocellular 12Ovarian Neoplasms 10Biliary Tract Neoplasms 9Adenocarcinoma Of Esophagus 9Esophageal Squamous Cell Carcinoma 8Cholangiocarcinoma 8Gastrointestinal Neoplasms 7Lymphoma, Non-Hodgkin 6Endometrial Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Carcinoma, Pancreatic Ductal 4Breast Neoplasms 4Advanced Solid Tumor 4Solid Tumors 3

Interventions

andecaliximab 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Injections 1Immunotherapy, Adoptive 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastric Adenocarcinoma × Oxaliplatin × Clear all
NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡